Protocol Ledger

NCT03732807 · Phase II/III · COMPLETED

PF-06651600 for the Treatment of Alopecia Areata

Interventional Phase II/III clinical trial protocol NCT03732807 sponsored by Pfizer in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-03 Enrollment: 718 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03732807
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)718 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03732807
Protocol FieldVerified Registry Value
NCT IdentifierNCT03732807
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment718 participants (ACTUAL)
Registered Start Date2018-12-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI